Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2008 1
2009 1
2010 4
2011 2
2012 3
2013 4
2014 3
2015 4
2016 4
2017 3
2018 9
2019 11
2020 17
2021 19
2022 14
2023 24
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib for the Treatment of Psoriatic Disease.
Lé AM, Puig L, Torres T. Lé AM, et al. Among authors: puig l. Am J Clin Dermatol. 2022 Nov;23(6):813-822. doi: 10.1007/s40257-022-00720-0. Epub 2022 Aug 12. Am J Clin Dermatol. 2022. PMID: 35960487 Free PMC article. Review.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.
Navarro-Compán V, Puig L, Vidal S, Ramírez J, Llamas-Velasco M, Fernández-Carballido C, Almodóvar R, Pinto JA, Galíndez-Aguirregoikoa E, Zarco P, Joven B, Gratacós J, Juanola X, Blanco R, Arias-Santiago S, Sanz Sanz J, Queiro R, Cañete JD. Navarro-Compán V, et al. Among authors: puig l. Front Immunol. 2023 Aug 4;14:1191782. doi: 10.3389/fimmu.2023.1191782. eCollection 2023. Front Immunol. 2023. PMID: 37600764 Free PMC article. Review.
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
Pinter A, Puig L, Schäkel K, Reich A, Zaheri S, Costanzo A, Tsai TF, Smith SD, Lynde C, Brnabic A, Reed C, Hill J, Schuster C, Riedl E, Paul C. Pinter A, et al. Among authors: puig l. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2087-2100. doi: 10.1111/jdv.18376. Epub 2022 Jul 29. J Eur Acad Dermatol Venereol. 2022. PMID: 35766124
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M. Kokolakis G, et al. Among authors: puig l. Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089. Br J Dermatol. 2023. PMID: 36751950 Clinical Trial.
105 results